Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
7 evidence topics · 7 sources
Preclinical intratumoral TGF-beta neutralization and durable response in head and neck xenografts
“TGFβ in tumors was neutralized by approximately 90% in animals dosed with 10 mg/kg of BCA101 compared with 54% in animals dosed with equimolar TGFβRII-Fc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patient-derived xenograft mouse models of head and neck squamous cell carcinoma, BCA101 showed durable response after dose cessation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma TGF-beta1 neutralization by dose in the phase 1 dose escalation
“Patients treated with ficerafusp alfa achieved complete and prolonged neutralization of TGF-β1 in plasma at weekly doses of ≥500 mg (Fig. 3A). Minimal neutralization of TGF-β2 was observed at doses of ≥500 mg (Fig. 3B). TGF-β3 levels were close to the lower limit of quantification and therefore not analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote